Who is the CEO of curacle?

According to the DART company overview, curacle's representative director is 유재현 (name as registered in Korean). The company was founded on 2016-05-12.

Where is curacle listed?

curacle trades on the Korea Exchange KOSDAQ market under the ticker 365270. Its fiscal year ends in December.

What were curacle's latest quarterly results?

In Q2 2026, curacle reported revenue of ₩7.2bn and operating profit of ₩2.4bn. Figures come from reports filed on DART.

Does curacle pay a dividend?

curacle did not pay a cash dividend for fiscal 2025, according to its annual report.

Which companies are in the same industry as curacle?

Under the Korean Standard Industrial Classification recorded on DART, curacle is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, D&D Pharmatech and LigaChem Biosciences.

curacle KRX:365270KOSDAQ

큐라클 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked16since Sep 11

In Q2 2026, curacle reported revenue of ₩7.2bn and operating profit of ₩2.4bn. curacle (큐라클) appeared in 0 Korean news articles and 0 DART filings over the past seven days.

curacle quarterly results separate, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩7.2bn	–	₩2.4bn margin 32.8%	₩3.2bn
Q1 2026	₩1.0bn	–	−₩3.0bn margin −285.9%	−₩3.1bn
Q4 2025 derived	₩0m	-100.0%	−₩4.7bn	−₩4.7bn
Q3 2025	₩7m	–	−₩2.9bn	−₩3.0bn
Q2 2025	–	–	−₩5.3bn	−₩6.3bn
Q1 2025	–	–	−₩3.6bn	−₩4.1bn
Q4 2024 derived	₩1.1bn	-11.0%	−₩2.4bn margin −213.3%	−₩4.1bn
Q3 2024	–	–	−₩3.3bn	−₩4.2bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

curacle top stories 2 weeks, by number of outlets

No story covered by multiple outlets in the past two weeks.

Latest curacle news Korean headlines

Oct 2105:59

Kucara CU01 to change diabetic kidney disease treatment paradigm as new option
팜뉴스
Oct 610:52
Curacle "presents clinical results of kidney disease treatment at international conference"
뉴시스경제
1 more on this story · 1 outlets
- Curacle presents phase 2b clinical results of kidney disease treatment at international conference ICDM글로벌경제신문 · Oct 6 16:57
Oct 610:23

Curacle presents CU01 phase 2b results at international diabetes conference… "accelerating follow-up development"
머니투데이
Oct 610:12
Curacle's CU01 presents phase 2b diabetic nephropathy results at ICDM
메디파나뉴스
1 more on this story · 1 outlets
- Curacle presents phase 2b results of diabetic nephropathy treatment CU01 at international conference파이낸셜뉴스 · Oct 6 15:37
Oct 610:11
Curacle presents CU01 phase 2b clinical results orally at ICDM 2026
뉴스핌
3 more on this story · 3 outlets
- Curacle presents CU01 diabetic nephropathy phase 2b results orally at ICDM 2026바이오타임즈 · Oct 6 11:26
- Curacle presents CU01 diabetic nephropathy phase 2b clinical results orally at ICDM 2026스페셜타임스 · Oct 6 12:11
- Curacle presents CU01 phase 2b clinical results orally at international diabetes conference팜뉴스 · Oct 6 16:57
Oct 610:09

Curacle presents CU01 phase 2b clinical results orally at International Conference on Diabetes Mellitus ICDM 2026
더바이오
Sep 2511:02

"Beyond VEGF blockade to vascular normalization"… Ingenia and Curacle compete in macular degeneration TIE2
이데일리
Sep 2317:32

Curacle expands development amid R&D cost decline… separating wheat from chaff ahead of retinal disease drug phase 2
시사저널e
Sep 2215:48

MajorCuracle pursuing follow-up clinical trials and early technology transfer simultaneously… "establishing commercial virtuous cycle"
머니투데이Licensing deal
Sep 2208:44
MajorMaptyx and Curacle selected for government project on AI-based vasculitis bispecific antibody MT-501
스페셜타임스Partnership
1 more on this story · 1 outlets
- Maptyx and Curacle selected for government project on vasculitis bispecific antibody MT-501글로벌경제신문 · Sep 22 15:54

Articles per day 2 weeks

Company profile

CEO: 유재현
Industry: Medical & pharmaceutical R&D
Founded: 2016-05-12
Fiscal year-end: December
Head office: 서울특별시 서초구
Website: curacle.com
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Same industry Medical & pharmaceutical R&D

All in industry

Company	Latest quarter op. profit	Articles 30d
Alteogen	–	255
D&D Pharmatech	−₩13.6bn	72
LigaChem Biosciences	−₩50.4bn	69
Curocell	−₩7.7bn	51
SillaJen	–	44
OliX Pharmaceuticals	–	42
Qurient	−₩7.0bn	41
GI Innovation	–	41

Compare curacle side by side with these companies

curacle DART filings

No filings yet.

Mentioned alongside 2 weeks

No co-mentioned companies yet.

curacle FAQ

Who is the CEO of curacle?: According to the DART company overview, curacle's representative director is 유재현 (name as registered in Korean). The company was founded on 2016-05-12.
Where is curacle listed?: curacle trades on the Korea Exchange KOSDAQ market under the ticker 365270. Its fiscal year ends in December.
What were curacle's latest quarterly results?: In Q2 2026, curacle reported revenue of ₩7.2bn and operating profit of ₩2.4bn. Figures come from reports filed on DART.
Does curacle pay a dividend?: curacle did not pay a cash dividend for fiscal 2025, according to its annual report.
Which companies are in the same industry as curacle?: Under the Korean Standard Industrial Classification recorded on DART, curacle is grouped with 53 other listed companies in medical & pharmaceutical r&d. The most covered in Korean news over the past 30 days are Alteogen, D&D Pharmatech and LigaChem Biosciences.